RT Journal Article
SR Electronic
T1 Unique Capabilities of Genome Sequencing for Rare Disease Diagnosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.08.23293829
DO 10.1101/2023.08.08.23293829
A1 Wojcik, Monica H
A1 Lemire, Gabrielle
A1 Zaki, Maha S
A1 Wissman, Mariel
A1 Win, Wathone
A1 White, Sue
A1 Weisburd, Ben
A1 Waddell, Leigh B
A1 Verboon, Jeffrey M
A1 VanNoy, Grace E.
A1 Töpf, Ana
A1 Tan, Tiong Yang
A1 Straub, Volker
A1 Stenton, Sarah L
A1 Snow, Hana
A1 Singer-Berk, Moriel
A1 Silver, Josh
A1 Shril, Shirlee
A1 Seaby, Eleanor G
A1 Schneider, Ronen
A1 Sankaran, Vijay G
A1 Sanchis-Juan, Alba
A1 Russell, Kathryn A
A1 Reinson, Karit
A1 Ravenscroft, Gianina
A1 Pierce, Eric A
A1 Place, Emily M
A1 Pajusalu, Sander
A1 Pais, Lynn
A1 Õunap, Katrin
A1 Osei-Owusu, Ikeoluwa
A1 Okur, Volkan
A1 Oja, Kaisa Teele
A1 O’Leary, Melanie
A1 O’Heir, Emily
A1 Morel, Chantal
A1 Marchant, Rhett G
A1 Mangilog, Brian E
A1 Madden, Jill A
A1 MacArthur, Daniel
A1 Lovgren, Alysia
A1 Lerner-Ellis, Jordan P
A1 Lin, Jasmine
A1 Laing, Nigel
A1 Hildebrandt, Friedhelm
A1 Groopman, Emily
A1 Goodrich, Julia
A1 Gleeson, Joseph G
A1 Ghaoui, Roula
A1 Genetti, Casie A
A1 Gazda, Hanna T
A1 Ganesh, Vijay S.
A1 Ganapathy, Mythily
A1 Gallacher, Lyndon
A1 Fu, Jack
A1 Evangelista, Emily
A1 England, Eleina
A1 Donkervoort, Sandra
A1 DiTroia, Stephanie
A1 Cooper, Sandra T
A1 Chung, Wendy K
A1 Christodoulou, John
A1 Chao, Katherine R
A1 Cato, Liam D
A1 Bujakowska, Kinga M
A1 Bryen, Samantha J
A1 Brand, Harrison
A1 Bonnemann, Carsten
A1 Beggs, Alan H
A1 Baxter, Samantha M
A1 Agrawal, Pankaj B
A1 Talkowski, Michael
A1 Austin-Tse, Chrissy
A1 Rehm, Heidi L
A1 O’Donnell-Luria, Anne
YR 2023
UL http://medrxiv.org/content/early/2023/08/13/2023.08.08.23293829.abstract
AB Background Causal variants underlying rare disorders may remain elusive even after expansive gene panels or exome sequencing (ES). Clinicians and researchers may then turn to genome sequencing (GS), though the added value of this technique and its optimal use remain poorly defined. We therefore investigated the advantages of GS within a phenotypically diverse cohort.Methods GS was performed for 744 individuals with rare disease who were genetically undiagnosed. Analysis included review of single nucleotide, indel, structural, and mitochondrial variants.Results We successfully solved 218/744 (29.3%) cases using GS, with most solves involving established disease genes (157/218, 72.0%). Of all solved cases, 148 (67.9%) had previously had non-diagnostic ES. We systematically evaluated the 218 causal variants for features requiring GS to identify and 61/218 (28.0%) met these criteria, representing 8.2% of the entire cohort. These included small structural variants (13), copy neutral inversions and complex rearrangements (8), tandem repeat expansions (6), deep intronic variants (15), and coding variants that may be more easily found using GS related to uniformity of coverage (19).Conclusion We describe the diagnostic yield of GS in a large and diverse cohort, illustrating several types of pathogenic variation eluding ES or other techniques. Our results reveal a higher diagnostic yield of GS, supporting the utility of a genome-first approach, with consideration of GS as a secondary or tertiary test when higher-resolution structural variant analysis is needed or there is a strong clinical suspicion for a condition and prior targeted genetic testing has been negative.Competing Interest StatementDGM is a paid advisor to GlaxoSmithKline, Insitro, Variant Bio and Overtone Therapeutics, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Google, Merck, Microsoft, Pfizer, and Sanofi-Genzyme. MHW has consulted for Illumina and Sanofi. HLR has received support from Illumina and Microsoft to support rare disease gene discovery and diagnosis. AODL has consulted for Tome Biosciences and Ono Pharma USA Inc, and is member of the scientific advisory board for Congenica Inc and the Simons Foundation SPARK for Autism study. STC is director of Frontier Genomics Pty Ltd (Australia) and receives no remuneration (salary or consultancy fees) for this role. Frontier Genomics Pty Ltd has no current financial interests that will benefit from publication of this data. WKC is on the Board of Directors of RallyBio and Prime Medicine.Funding StatementThe Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) was funded by the National Human Genome Research Institute (NHGRI), the National Eye Institute, the National Heart, Lung and Blood Institute grant UM1HG008900 and NHGRI grants U01HG011755 and R01HG009141. This publication has also been made possible in part by CZI grant DAF2019 19927 (grant DOI https://doi.org/10.37921/236582yuakxy) from the Chan Zuckerberg Initiative DAF an advised fund of Silicon Valley Community Foundation (funder DOI 10.13039/100014989). FH is supported by NIH 5RC-2DK122397. SP is supported by Estonian Research Council grants PUTJD827, MOBTP175, PSG774. KO, KR and KTO are supported by Estonian Research Council grant PRG471. UDP-Vic receives financial support from the Murdoch Children's Research Institute and the Harbig Foundation. The research conducted at the Murdoch Children's Research Institute (MCRI) was supported by the Victorian Government's Operational Infrastructure Support Program. The Chair in Genomic Medicine awarded to JC is generously supported by The Royal Children's Hospital Foundation. MYOSEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, Samantha J Brazzo Foundation, LGMD2D Foundation, Kurt+Peter Foundation, Muscular Dystrophy UK and Coalition to Cure Calpain 3. CGB is supported by intramural funds by the NIH National Institute of Neurological Disorders and Stroke. JLE was funded by the McLaughlin Centre (grant MC201213, MC2014111 and MC201712) and CIHR - Champions of Genetics: Building the Next Generation Grant (FRN: 135730). MHW is supported by NIH K23 HD102589, NIH R21 HG012397, and by an early career award from the Thrasher Research Fund. KMB and EAP are supported by grants from the National Eye Institute: R01 EY026904 (KMB/EAP), R01 EY012910 (EAP) and P30 EY014104 (MEEI core support), the Foundation Fighting Blindness: EGI-GE-1218-0753-UCSD, (KMB) and the Research to Prevent Blindness International Research Collaborators Award (KMB). ADD is supported by NIH R01 HD081256, MH 115957. The Rare Disease Flagship acknowledges financial support from the Royal Children's Hospital Foundation, the Murdoch Children's Research Institute and the Harbig Foundation. NGL is supported by the Australian National Health and Medical Research Council (NHMRC) Grant APP2002640. STC received support from National Health and Medical Research Council (NHMRC) of Australia Fellowships APP1048816 and APP1136197,, NHMRC Project Grant APP1080587 and NHMRC Ideas Grants APP1106084, APP2002640. SJB received a Muscular Dystrophy Association of New South Wales Sue Connor postgraduate training scholarship. RG was supported by NHMRC grant APP1074954. SLS is supported by a fellowship from the Manton Center for Orphan Disease Research at Boston Children's Hospital. GR is supported by a NHMRC EL2 Fellowship (APP2007769).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Mass General Brigham gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001272.v1.p1